Trial Profile
A Phase I Dose Escalation Trial to Determine if Imatinib Treatment Restores Sodium Iodide Symporter Function and Sensitivity to Radioiodine Treatment in Metastatic Thyroid Cancer Patients
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Feb 2023
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Thyroid cancer
- Focus Pharmacodynamics
- 01 Feb 2023 Planned End Date changed from 31 Dec 2021 to 31 Dec 2023.
- 01 Feb 2023 Planned primary completion date changed from 31 Dec 2021 to 31 Dec 2023.
- 26 Jun 2021 Planned End Date changed from 31 Dec 2020 to 31 Dec 2021.